infections. There was no leukemic transformation or deaths in our study group.

**Conclusion**

Timely and early referral to specialist services will not only prevent morbidity, enable appropriate follow up with early recognition of complications and institution of preventive patient care but also promote family’s understanding of and coping with the syndrome.

**PS-086 QUESTIONNAIRE STUDY FOR ASSESSMENT OF QUALITY OF LIFE (QOL) IN CHILDREN WITH SWIDAMON CHD SYNDROME (SDS)**

1A Shukla, 1E Kinsey, 1Pun, 1Department of Paediatrics, Leeds General Infirmary, Leeds, UK; 2Department of Paediatric Haematology, Leeds General Infirmary, Leeds, UK; 3Department of Paediatric Gastroenterology, Leeds General Infirmary, Leeds, UK

SDS is a multisystem disorder with heterogeneous clinical presentation. Neuro-cognitive impairments, intellectual disability and behavioural difficulties have been reported in previous studies.

**Methods and patients**

We used validated child and parent reporting questionnaires (CHQ-CF87, CHQ-PF50) to explore QoL in children with SDS aged 5–18 years (followed at SDS multidisciplinary clinic at Leeds). 7 children and 1 of their parent completed the self-administered questionnaires. Data was analysed and interpreted as per scoring and interpretation manual provided with the questionnaires. Ethics approval was obtained.

**Results**

Parents scored their child below reference sample for global health and behaviour; they recognised that they worried about their child’s health more than other people. There was discrepancy in scoring on some health domains between child and parent CHQ which could represent child’s lack of insight or better scoring by parents comparing their child’s health and behaviour with their peers.

Qualitative analysis revealed that majority of children reported good health and all experienced mild pain or discomfort. Most were happy, got on with friends, but admitted to arguing and recognised their health/behaviour caused family tension.

Parents reported difficulty concentrating, paying attention and argumentative behaviour. They expressed uncertainty about their child having a healthy life and reported their health/behaviour caused disruption of everyday family activities. Some parents reported their children having difficulties in activities like eating, dressing or going to toilet alone.

**Conclusions**

Our findings identify important qualitative areas of concern and highlight potential areas for providing targeted support to children with SDS and their families.

**PS-087 WITHDRAWN**

**PS-088 TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA BY PREDNISOLONE: 4 MG/KG/J FOR 4 DAYS VERSUS 2 MG/KG/J FOR 6–8 WEEKS**

1M Slaibhi, 1S Ali, 1I Djeddi, 1S Ben Amer, 1I Damak, 1M Hachicha, 1Pediatrics, Hedi Chaker University Hospital, Sfax, Tunisia; 2Community Medicine and Epidemiology, Hedi Chaker University Hospital, Sfax, Tunisia

**Background and aims**

Primary immune thrombocytopenia (ITP) is characterised by accelerated platelet destruction. Corticosteroids have been shown to increase platelet counts. The objective of our study was to compare the treatment with prednisolone at a dose of 4 mg / kg / day for 4 days (Protocol P1) to the treatment with prednisolone at the dose of 2 mg / kg / day for 6–8 weeks (Protocol P2).

**Methods**

We conducted a comparative analytical study between 2 groups: first group (G1) formed by ITP cases followed prospectively between 2010 and 2013. These patients received protocol P1. The second group (G2) collecting the same number of patients followed retrospectively between 1999 and 2008. These patients received protocol P2.

**Results**

Our study included 24 cases: 12 cases in G1 and 12 cases in G2. The response on day three was 25% for G1 and 0% for G2. The response on the fifth day was 66.7% (G1) and 54.5% (G2). The median time to response was 5 days for the 2 groups, with extremes ranging from 3 to 30 days (G1) and 5 to 30 days (G2) (p: 0.09). The complete response occurred in 15 days with a range of 5–90 days for G1 and 30 days with a range of 5–90 days for G2 (p = 0.04).

**Conclusion**

Within the limits of our study, we are able to show the interest of high dose of prednisolone during 4 days in the treatment of acute ITP.